Journal Article

DZNE-2026-01166

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png The GFAP/NfL ratio does not outperform NfL or GFAP in genetic frontotemporal dementia.

De Houwer, J. F. H. ; Dopper, E. G. ; van Buuren, R. ; de Boer, L. ; Swartenbroekx, T. ; Rajicic, A. ; Sogorb-Esteve, A. ; Bouzigues, A. ; Russell, L. L. ; Foster, P. H. ; Ferry-Bolder, E. ; Sanchez-Valle, R. ; Laforce, R. ; Graff, C. ; Galimberti, D. ; Vandenberghe, R. ; de Mendonça, A. ; di Fede, G. ; Santana, I. ; Gerhard, A. ; Levin, J.DZNE* ; Nacmias, B. ; Otto, M. ; Bertoux, M. ; Lebouvier, T. ; Ducharme, S. ; Butler, C. R. ; Ber, I. L. ; Finger, E. ; Tartaglia, M. C. ; Masellis, M. ; Rowe, J. B. ; Synofzik, M.DZNE* ; Moreno, F. ; Borroni, B. ; Zetterberg, H. ; Pijnenburg, Y. A. L. ; Teunissen, C. ; Jiskoot, L. C. ; van Swieten, J. C. ; Rohrer, J. D. ; Seelaar, H.

2026
Wiley Hoboken, NJ

This record in other databases:    

Please use a persistent id in citations: doi:10.1002/dad2.70483

Abstract: We investigated the diagnostic utility of the plasma glial fibrillary acidic protein (GFAP)/neurofilament light chain (NfL) ratio in genetic frontotemporal dementia (FTD) and compared its performance with GFAP and NfL alone.Baseline plasma samples were available from 391 pathogenic variant carriers and non-carriers, with longitudinal samples (≥2) from 259 participants. Linear mixed-effects models were used to assess baseline differences between clinical groups, longitudinal trajectories, and the ability of the GFAP/NfL ratio to discriminate underlying TAR DNA-binding protein (TDP) versus tau pathology.Baseline GFAP/NfL ratios differed across clinical groups; however, the ratio did not outperform GFAP or NfL alone in any clinically relevant comparison. No significant differences were observed between symptomatic carriers with underlying TDP versus tau pathology.The GFAP/NfL ratio provides no added value over NfL alone as a diagnostic or susceptibility biomarker in genetic FTD.

Keyword(s): biomarker ; frontotemporal dementia ; genetic ; glial fibrillary acidic protein ; neurofilament light chain

---

Contributing Institute(s):

1. Clinical Neurodegeneration (AG Levin)
2. Clinical Research (Munich) (Clinical Research (Munich))
3. Parkinson Genetics (AG Gasser)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

---

Database coverage:
; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; DEAL Wiley ; DOAJ Seal ; Emerging Sources Citation Index ; Fees ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Web of Science Core Collection

---